| Outcomes of COVID-19 in patients with CLL: a multicenter international experience AR Mato, LE Roeker, N Lamanna, JN Allan, L Leslie, JM Pagel, K Patel, ... Blood, The Journal of the American Society of Hematology 136 (10), 1134-1143, 2020 | 298 | 2020 |
| Risk of breast implant associated anaplastic large cell lymphoma (BIA-ALCL) in a cohort of 3546 women prospectively followed long term after reconstruction with textured breast … PG Cordeiro, P Ghione, A Ni, Q Hu, N Ganesan, N Galasso, A Dogan, ... Journal of Plastic, Reconstructive & Aesthetic Surgery 73 (5), 841-846, 2020 | 169 | 2020 |
| Clinical and biological subtypes of B-cell lymphoma revealed by microenvironmental signatures N Kotlov, A Bagaev, MV Revuelta, JM Phillip, MT Cacciapuoti, ... Cancer discovery 11 (6), 1468-1489, 2021 | 145 | 2021 |
| Minimal residual disease detection by droplet digital PCR in multiple myeloma, mantle cell lymphoma, and follicular lymphoma: a comparison with real-time PCR D Drandi, L Kubiczkova-Besse, S Ferrero, N Dani, R Passera, B Mantoan, ... The Journal of Molecular Diagnostics 17 (6), 652-660, 2015 | 142 | 2015 |
| KMT2D mutations and TP53 disruptions are poor prognostic biomarkers in mantle cell lymphoma receiving high-dose therapy: a FIL study S Ferrero, D Rossi, A Rinaldi, A Bruscaggin, V Spina, CW Eskelund, ... haematologica 105 (6), 1604-1612, 2020 | 132 | 2020 |
| Impaired humoral responses to COVID-19 vaccination in patients with lymphoma receiving B-cell–directed therapies P Ghione, JJ Gu, K Attwood, P Torka, S Goel, S Sundaram, C Mavis, ... Blood, The Journal of the American Society of Hematology 138 (9), 811-814, 2021 | 98 | 2021 |
| Combinatorial targeting of nuclear export and translation of RNA inhibits aggressive B-cell lymphomas B Culjkovic-Kraljacic, TM Fernando, R Marullo, N Calvo-Vidal, A Verma, ... Blood, The Journal of the American Society of Hematology 127 (7), 858-868, 2016 | 90 | 2016 |
| A phase 2 biomarker-driven study of ruxolitinib demonstrates effectiveness of JAK/STAT targeting in T-cell lymphomas AJ Moskowitz, P Ghione, E Jacobsen, J Ruan, JH Schatz, S Noor, ... Blood, The Journal of the American Society of Hematology 138 (26), 2828-2837, 2021 | 81 | 2021 |
| Bendamustine and rituximab combination is safe and effective as salvage regimen in Waldenström macroglobulinemia A Tedeschi, P Picardi, S Ferrero, G Benevolo, G Margiotta Casaluci, ... Leukemia & lymphoma 56 (9), 2637-2642, 2015 | 75 | 2015 |
| AICDA drives epigenetic heterogeneity and accelerates germinal center-derived lymphomagenesis M Teater, PM Dominguez, D Redmond, Z Chen, D Ennishi, DW Scott, ... Nature communications 9 (1), 222, 2018 | 73 | 2018 |
| T-cell lymphomas, version 2.2022, NCCN clinical practice guidelines in oncology SM Horwitz, S Ansell, WZ Ai, J Barnes, SK Barta, J Brammer, ... Journal of the National Comprehensive Cancer Network 20 (3), 285-308, 2022 | 68 | 2022 |
| T follicular helper phenotype predicts response to histone deacetylase inhibitors in relapsed/refractory peripheral T-cell lymphoma P Ghione, P Faruque, N Mehta-Shah, V Seshan, N Ozkaya, S Bhaskar, ... Blood advances 4 (19), 4640-4647, 2020 | 63 | 2020 |
| Minimal residual disease detection in lymphoma and multiple myeloma: impact on therapeutic paradigms S Ferrero, D Drandi, B Mantoan, P Ghione, P Omedè, M Ladetto Hematological oncology 29 (4), 167-176, 2011 | 49 | 2011 |
| Clinical characteristics and outcomes of extranodal stage I diffuse large B-cell lymphoma in the rituximab era S Bobillo, E Joffe, JA Lavery, D Sermer, P Ghione, A Noy, PC Caron, ... Blood, The Journal of the American Society of Hematology 137 (1), 39-48, 2021 | 47 | 2021 |
| Prophylaxis with intrathecal or high-dose methotrexate in diffuse large B-cell lymphoma and high risk of CNS relapse S Bobillo, E Joffe, D Sermer, P Mondello, P Ghione, PC Caron, ... Blood cancer journal 11 (6), 1-6, 2021 | 46 | 2021 |
| Lenalidomide in relapsed or refractory diffuse large B-cell lymphoma: is it a valid treatment option? P Mondello, N Steiner, W Willenbacher, S Ferrero, P Ghione, A Marabese, ... The oncologist 21 (9), 1107-1112, 2016 | 43 | 2016 |
| Comparative effectiveness of ZUMA-5 (axi-cel) vs SCHOLAR-5 external control in relapsed/refractory follicular lymphoma P Ghione, ML Palomba, AR Patel, S Bobillo, K Deighton, CA Jacobson, ... Blood, The Journal of the American Society of Hematology 140 (8), 851-860, 2022 | 42 | 2022 |
| Bendamustine plus rituximab versus R-CHOP as first-line treatment for patients with indolent non-Hodgkin’s lymphoma: evidence from a multicenter, retrospective study P Mondello, N Steiner, W Willenbacher, I Wasle, F Zaja, R Zambello, ... Annals of Hematology 95, 1107-1114, 2016 | 41 | 2016 |
| Prospective molecular monitoring of minimal residual disease after non-myeloablative allografting in newly diagnosed multiple myeloma M Ladetto, S Ferrero, D Drandi, M Festuccia, F Patriarca, N Mordini, ... Leukemia 30 (5), 1211-1214, 2016 | 41 | 2016 |
| Mantle cell lymphoma–Current standards of care and future directions P Martin, P Ghione, M Dreyling Cancer treatment reviews 58, 51-60, 2017 | 32 | 2017 |
Steven HorwitzMemorial Sloan Kettering Cancer CenterVerified email at mskcc.org
